Format

Send to

Choose Destination
See comment in PubMed Commons below
Mult Scler. 2009 Feb;15(2):272-4. doi: 10.1177/1352458508097468. Epub 2009 Jan 9.

Daclizumab in treatment of multiple sclerosis patients.

Author information

  • 1Partners MS Center, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. eman_c5@yahoo.com

Abstract

BACKGROUND:

Daclizumab is a humanized monoclonal antibody (mAb) that blocks the interleukin-2 receptor alpha subunit (IL-2R-alpha chain; CD25) expressed on activated T cells leading to the inhibition of T-cell expansion, thus strongly reduces brain inflammation in patients with multiple sclerosis (MS). Another mechanism is significant expansion of CD56 (bright) natural killer (NK) cells that in turn inhibit T-cell survival.

OBJECTIVE:

At the Partners MS center, we have been using Daclizumab in an open-label fashion in patients who fail first line therapy or non-standard immunosuppressive treatment. Our aim was to assess its safety and tolerability in our patient population.

PMID:
19136546
DOI:
10.1177/1352458508097468
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center